PCM
CRBP icon

Prelude Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Prelude Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-383
Closed -$23K – 1685
2021
Q1 		$23K Buy
+383
New +$25.2K ﹤0.01% 1478
2020
Q4 		– Sell
-157
Closed -$8K – 1391
2020
Q3 		$8K Buy
+157
New +$28.4K ﹤0.01% 1483

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prelude Capital Management's CRBP Position: Q1 2026 in Review

Prelude Capital Management increased its Corbus Pharmaceuticals (CRBP) stake by 186% in Q1 2026, buying an estimated $278K and bringing the position to 50,826 shares worth $477K. The position accounts for 0.04% of the portfolio, ranked #533.

Prelude Capital Management first reported a position in CRBP in Q1 2024 and has held it in 7 quarters since. The position peaked at $847K in Q3 2025. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Prelude Capital Management held 50,826 shares of Corbus Pharmaceuticals worth $477K as of Q1 2026.
  • Prelude Capital Management bought 33,045 Corbus Pharmaceuticals shares in Q1 2026, an estimated $278K.
  • Corbus Pharmaceuticals made up 0.04% of Prelude Capital Management's portfolio in Q1 2026, its #533 holding.
  • Prelude Capital Management first reported a position in Corbus Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
  • Prelude Capital Management's Corbus Pharmaceuticals position peaked at $847K in Q3 2025.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.